HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)

HLB Pharmaceutical Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Net Income	3,723	4,572	2,020	472.65	-7,060	-5,447
Depreciation & Amortization	4,332	4,112	5,089	1,640	1,143	1,055
Loss (Gain) From Sale of Assets	20.48	-52.53	-520.94	2.08	31.53	0.62
Asset Writedown & Restructuring Costs	32.67	32.67	12,215	438.73	-	509.63
Loss (Gain) From Sale of Investments	-267.01	-267.01	-15,885	-120.89	-164.96	137.71
Loss (Gain) on Equity Investments	-2,532	-2,324	1,121	-	-	-
Stock-Based Compensation	102.49	173.44	288.54	105.02	431.59	454.54
Provision & Write-off of Bad Debts	-14.52	-90.2	17.56	124.02	16.52	-40.69
Other Operating Activities	-194.59	-502.68	1,980	943.5	2,269	2,425
Change in Accounts Receivable	-3,310	836.54	2,471	-1,990	1,253	2,198
Change in Inventory	-3,246	-3,891	-1,370	-266.03	-397.13	-2,194
Change in Accounts Payable	1,362	-2,483	1,758	-2,452	946.47	-253.52
Change in Other Net Operating Assets	2,221	453.15	-2,343	2,456	-246.42	370.51
Operating Cash Flow	2,231	568.98	6,841	1,353	-1,777	-784.3
Operating Cash Flow Growth	-67.39%	-91.68%	405.50%	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Capital Expenditures	-9,598	-7,210	-2,799	-1,397	-1,095	-2,236
Sale of Property, Plant & Equipment	114.2	103	572.95	4	24.01	3.4
Divestitures	-	-	-	-	937.48	-
Sale (Purchase) of Intangibles	-2.1	-	-292.13	-540.15	-280.15	-192.6
Investment in Securities	2,236	3,236	-9,704	-5,058	617.85	3,559
Other Investing Activities	-17,117	-17,448	-34	43.27	105	37.98
Investing Cash Flow	-24,368	-21,319	-12,256	-6,938	309.09	1,172

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Short-Term Debt Issued	-	-	10,000	1,892	-	1,725
Long-Term Debt Issued	-	-	903.09	10,914	-	1,400
Total Debt Issued	-	-	10,903	12,806	-	3,125
Short-Term Debt Repaid	-	-	-	-5,546	-371.25	-1,400
Long-Term Debt Repaid	-	-1,168	-1,045	-1,961	-480	-580
Total Debt Repaid	-1,299	-1,168	-1,045	-7,507	-851.25	-1,980
Net Debt Issued (Repaid)	-1,299	-1,168	9,859	5,299	-851.25	1,145
Issuance of Common Stock	19,035	19,035	1,283	-	-	-
Financing Cash Flow	17,736	17,867	11,141	5,299	-851.25	1,145

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Foreign Exchange Rate Adjustments	-	-	-	-	-0.35	3,833
Miscellaneous Cash Flow Adjustments	0	0	0	-	-	-
Net Cash Flow	-4,401	-2,883	5,726	-286.08	-2,320	5,365

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Free Cash Flow	-7,368	-6,642	4,042	-43.8	-2,872	-3,020
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Margin	-3.11%	-3.23%	2.95%	-0.12%	-13.98%	-19.41%
Free Cash Flow Per Share	-223.68	-203.19	126.07	-3.16	-212.19	-252.31
Levered Free Cash Flow	-	-15,677	-	1,808	-540.14	-
Unlevered Free Cash Flow	-	-15,216	-	2,554	-2.9	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Cash Interest Paid	739.62	740.77	698.18	288.41	207.01	274.48
Cash Income Tax Paid	56.93	55.79	-18.35	58.82	17.4	4.95
Change in Working Capital	-2,973	-5,084	516.46	-2,252	1,556	120.3

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 3, 2026

Data Sources Report a data error